United Pharmaceuticals delivers robust liquid chromatography–mass spectrometry (LC–MS) and hybrid LC–MS bioanalytical solutions designed to support drug development from early discovery through late-stage clinical trials. Our bioanalytical strategies combine advanced instrumentation, scientifically rigorous methods, and regulatory-aligned workflows to generate precise, sensitive, and reproducible data across diverse therapeutic programs.
Our laboratories support both preclinical and clinical studies, producing high-quality pharmacokinetic, toxicokinetic, and biomarker data that enable confident, data-driven decisions at every stage of development.
With extensive experience in LC–MS/MS bioanalysis, our scientific teams support a wide range of therapeutic modalities and biological matrices. We apply high-sensitivity and high-selectivity methods for accurate quantification across both regulated and non-regulated studies.
Our LC–MS and hybrid LC–MS capabilities support:
Hybrid LC–MS workflows are strategically applied to large molecule programs to improve assay sensitivity, specificity, and robustness, particularly in complex biological matrices encountered in clinical and translational studies.
United Pharmaceuticals provides end-to-end bioanalytical support tailored to your molecule, matrix, and development phase. Our services are designed to integrate seamlessly with preclinical and clinical programs while meeting regulatory expectations.
We deliver accurate and reproducible quantification of small molecules, peptides, proteins, monoclonal antibodies, antibody–drug conjugates, and oligonucleotides using validated LC–MS/MS methodologies.
Our teams support high-sensitivity biomarker detection and quantification to accelerate early-phase development, translational research, and mechanism-of-action studies.
By integrating immunoaffinity enrichment with LC–MS analysis, we enhance assay selectivity and sensitivity, particularly for low-abundance large molecules and protein biomarkers.
We generate high-quality bioanalytical data to support pharmacokinetic and pharmacodynamic studies, enabling accurate assessment of drug absorption, distribution, metabolism, and elimination.
Our workflows incorporate microsampling technologies to support low-volume blood collection in both preclinical and clinical settings, improving study feasibility and reducing burden on subjects.
We provide critical analytical data to support formulation development, comparative studies, and regulatory submissions related to bioavailability and bioequivalence.
We conduct both Good Laboratory Practice and non-Good Laboratory Practice studies, ensuring data integrity, traceability, and compliance across all phases of development.
Whether evaluating early-stage candidates or supporting pivotal clinical studies, our LC–MS and hybrid LC–MS bioanalytical solutions are customized to meet program-specific requirements. We align analytical strategies with study objectives, timelines, and regulatory expectations to deliver reliable data that advances development efficiently.
United Pharmaceuticals offers high-precision, reproducible LC–MS/MS bioanalytical services designed to support single studies or fully integrated development programs. Our collaborative approach ensures that bioanalytical strategies are tailored to your compound characteristics, matrices, and therapeutic goals.
Key differentiators include: